Physician

Abdul Sankari, M.D.

According to 2025 Medicare claims, Abdul Sankari, M.D. (NPI: 1326097239) practices cardiology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Will, IL. This provider's primary affiliated billing organization is DUPAGE MEDICAL GROUP LTD (NPI: 1801833983; TIN: 36-2657618) and primary practice location at 60451-9509. Sankari is affiliated with the DULY HEALTH AND CARE ACCOUNTABLE CARE ORGANIZATION (ACO ID: D0265), participating under the REACH model.

Sankari's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,170 traditional Medicare patients, billed 8,146 HCPCS/CPT codes, and received $629,129 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 10,391 prescription claims across 1,500 beneficiaries totaling $1,784,876 in drug costs, led by Eliquis (Apixaban). 2020 DME data shows 16 claims. Open Payments data shows 11 records totaling $246. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $377,510 to $1,784,876. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,878	7,916	$614,886
2016	2,163	6,411	$648,295
2017	2,894	8,072	$710,696
2018	3,437	8,554	$612,169
2019	2,561	7,241	$586,250
2020	3,749	8,212	$650,443
2021	3,304	8,020	$697,459
2022	2,441	7,086	$654,125
2023	2,057	6,398	$560,613
2024	2,170	8,146	$629,129

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	572	5,915	$377,510
2016	598	5,633	$399,763
2017	666	5,541	$450,086
2018	652	5,249	$477,308
2019	675	5,578	$565,361
2020	893	6,572	$702,411
2021	1,155	8,048	$935,393
2022	1,333	8,850	$1,229,883
2023	1,380	9,353	$1,637,955
2024	1,500	10,391	$1,784,876

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	13	$28,983
2020	N/R	16	$31,710
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	1,076	1,099	$123
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	251	663	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,073	1,525	$93
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	823	986	$13
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	609	629	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	559	39,403	$751,281
Entresto	Sacubitril/Valsartan	275	16,518	$357,959
Xarelto	Rivaroxaban	184	11,552	$215,082
Brilinta	Ticagrelor	91	5,493	$80,140
Repatha Sureclick	Evolocumab	63	3,724	$71,367

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$246	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdul Sankari, M.D.?

Tedicare shows public-source Medicare data for Abdul Sankari, M.D. (NPI 1326097239), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdul Sankari, M.D. have ACO affiliation data?

Abdul Sankari, M.D. is shown with ACO affiliation data for DULY HEALTH AND CARE ACCOUNTABLE CARE ORGANIZATION (REACH, ACO ID D0265).

What billing organization is linked to Abdul Sankari, M.D.?

Abdul Sankari, M.D. is linked to DUPAGE MEDICAL GROUP LTD (billing NPI 1801833983) in the available physician profile data.

Does Abdul Sankari, M.D. have Open Payments data?

Abdul Sankari, M.D. has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.